We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Peptidomimetics Creates New Possibilities in Drug Discovery

Pink and blue, white and red pill capsules on a white background.
Credit: Thought Catalog/ Unsplash
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Researchers at the University of Birmingham, in collaboration with the Universities of Bristol and Leeds, successfully demonstrated a route by which peptides could be modified to make them promising reagents for disease diagnostics and drug discovery. 

Traditional targets in drug discovery are enzymes such as proteases and kinases. These proteins are attractive targets because they have well defined ‘binding sites’ for their substrates – the molecules with which the enzymes interact. It is now relatively straightforward to develop molecules that mimic the substrate and which inhibit or modify the function of the target.   

In contrast, interactions between proteins – so called protein-protein interaction (PPIs) – regulate most biological functions, including that of enzymes. PPIs are far more numerous than traditional drug discovery targets, so blocking PPIs potentially opens-up a much wider range of drug targets.   

PPIs have traditionally been considered too difficult to use as drug targets, however, because their binding sites are larger, with fewer grooves or pockets to which small molecule compounds can bind. Understanding how PPIs occur and how to control this represents a first step towards drug discovery against these important targets.  

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE
In the new study, published in Chemical Science, the team focused on a PPI that involves β-strand formation at the interface. A β-strand is a specific type of secondary structure that is used to build 3D structure in proteins. By taking a small peptide sequence from the part of the protein where the β-strand forms, and making modifications to its backbone, the team were able to show it binds more quickly and more strongly to the target. 

“Our modification uses relatively simple chemistry and has taught us about how peptides bind to their targets in a β-strand conformation and how to control binding,” said lead researcher Professor Andy Wilson.

“This in turn opens up the path to drug discovery for β-strand mediated PPIs targets.”

The team has shown how this could be done for one specific type of PPI – the SIM/SUMO interaction, which in itself plays fundamental roles in protein stability, response to stress and the cell cycle. The next steps will be to demonstrate the approach can be generalised for multiple different PPIs.

Reference: Cawood EE, Baker E, Edwards TA, Woolfson DN, Karamanos TK, Wilson AJ. Understanding β-strand mediated protein–protein interactions: tuning binding behaviour of intrinsically disordered sequences by backbone modification. Chem Sci. 2024. doi: 10.1039/D4SC02240H

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.